International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension

V.V. Zakharov

Sechenov First Moscow State Medical University (Sechenov University)

SPIN RSCI: 6404-1030
Scopus AuthorID: 7402991374
ORCID: 0000-0002-8447-3264

O.D. Ostroumova

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University);
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

SPIN RSCI: 3910-6585
Scopus AuthorID: 7004067629
ResearcherID: M-9553-2014
ORCID: 0000-0002-0795-8225

A.I. Kochetkov

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0001-5801-3742

A.I. Fedin

Pirogov Russian National Research Medical University

SPIN RSCI: 8834-0085
Scopus AuthorID: 7007163263
ORCID: 0000-0002-6996-2828

Journal: Russian Journal of Preventive Medicine. 2024;27(10): 72–83

International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension

Authors:

V.V. Zakharov, O.D. Ostroumova, A.I. Kochetkov, A.I. Fedin

More about the authors

DOI: 10.17116/profmed20242710172

Read: 3079 times

Open to cite this article

Zakharov VV, Ostroumova OD, Kochetkov AI, Fedin AI. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;27(10):72‑83. (In Russ., In Engl.).
https://doi.org/10.17116/profmed20242710172

Close metadata

MATERIAL AND METHODS

In a subanalysis patients with CBI were divided into four subgroups: 1^st — AH patients receiving Mexidol and Mexidol FORTE 250 (n=144); 2^nd — AH patients receiving placebo (n=146); 3^rd — patients without AH receiving Mexidol and Mexidol FORTE 250 (n=15); 4^th — patients without AH receiving placebo (n=12).

RESULTS

At the end of the follow-up, significant differences were found in the dynamics of the MoCA scores between the patients receiving Mexidol and placebo (p=0.000), which allows to state a superior efficacy of Mexidol in the subgroup of patients with AH. Also in the long-term sequential therapy with Mexidol, in contrast to the placebo, the median value of the MoCA score at the end of the follow-up reached normal levels in patients with and without AH. When assessing secondary efficacy endpoints, a significant advantage of Mexidol over placebo in the population of patients with AH at the end of follow-up was achieved on the following parameters: The Digit Symbol Substitution Test, MFI-20, the Beck Anxiety Inventory, Tinetti Performance-Oriented Mobility Assessment, psychological component of health according to SF-36 questionnaire. A comparable character of the safety profile of Mexidol and placebo was established.

CONCLUSION

The obtained results allow to recommend the use of long-term sequential therapy with Mexidol in the complex therapy of patients with AH and CBI as a tool for the brain protection as a AH target organ and as a tool of pathogenetically substantiated therapy of cognitive, emotional, asthenic, vegetative and motor disorders.

Keywords:

chronic brain ischemia

arterial hypertension

cognitive impairment

ethylmethylhydroxypyridine succinate

Mexidol

Mexidol FORTE 250

Authors:

V.V. Zakharov

Sechenov First Moscow State Medical University (Sechenov University)

SPIN RSCI: 6404-1030
Scopus AuthorID: 7402991374
ORCID: 0000-0002-8447-3264

O.D. Ostroumova

SPIN RSCI: 3910-6585
Scopus AuthorID: 7004067629
ResearcherID: M-9553-2014
ORCID: 0000-0002-0795-8225

A.I. Kochetkov

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0001-5801-3742

A.I. Fedin

Pirogov Russian National Research Medical University

SPIN RSCI: 8834-0085
Scopus AuthorID: 7007163263
ORCID: 0000-0002-6996-2828

Received:

28.08.2024

Accepted:

02.09.2024

Conflict of Interest :

The article was prepared with the support of the pharmaceutical company Vectorpharm.

List of references:

Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7–16 (In Russ.). https://doi.org/10.17116/jnevro20211211117
Zakharov VV, Sleptsova KB, Martynova OO. Chronic cerebral ischemia: a view from the XXI century. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2021;29(5):45–49 (In Russ.)].
Tabeeva GR. Clinical phenomenology, mechanisms of formation and pathogenetic therapy of early manifestations of chronic brain ischemia. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2015; 24(4):11–17 (In Russ.)].
Martynov AI, Vertkin AL, Danilov AB, et al. Consensus for the management of patients with chronic ischemia of the brain for therapists and general practitioners. Terapiya = Therapy. 2020;6(7):15–21 (In Russ.). https://doi.org/10.18565/therapy.2020.7.14-21.
Azarpazhooh MR, Hachinski V. Vascular cognitive impairment: A preventable component of dementia. Handb Clin Neurol. 2019;167: 377–91. https://dx.doi.org/10.1016/B978-0-12-804766-8.00020-0
Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. Date of access — 14.01.2023. (In Russ.). https://cr.minzdrav.gov.ru/schema/62_2
Di Chiara T, Del Cuore A, Daidone M, et al. Pathogenetic mechanisms of hypertension-brain-induced complications: Focus on molecular mediators. Int J Mol Sci. 2022;23(5):2445. https://dx.doi.org/10.3390/ijms23052445
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019;40(5):475]. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339.
Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, et al. Efficacy and safety of Mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8–2):49–57 (In Russ.)]. https://doi.org/10.17116/jnevro202012008249
Bolotova EV, Lushpay NYu, Kovrigina IV. Improvement of the efficacy of treatment of hypertensive encephalohathy by using Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(4):61–64 (In Russ.). https://doi.org/10.17116/jnevro20181184161-64.
Chukanova EI, Chukanova AS, Mamayeva KhI. The results of the study of the efficacy and safety of Mexidol in patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(2):71–74 (In Russ.). https://doi.org/10.17116/jnevro20151152171-74.
Chukanova EI, Chukanova AS, Mamaeva KhI. The efficacy of antioxidant treatment with Mexidol FORTE in 250 patients with chronic cerebral venous insufficiency. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3):57–63 (In Russ.). https://doi.org/10.17116/jnevro202112103157.
Bogolepova AN. The role of oxidative stress in the development of vascular cognitive disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):133–139 (In Russ.). https://doi.org/10.17116/jnevro2020120081133.
Chukanova EI, Chukanova AS. Efficacy and safety of the drug Mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39–45 (In Russ.). https://doi.org/10.17116/jnevro201911909139
Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment [published correction appears in J Am Geriatr Soc. 2019;67(9):1991]. J Am Geriatr Soc. 2005;53(4):695–99. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Zakharov VV. Neuropsychological tests. Necessity and possibility of application. Consilium Medicum. 2011;13(2):98–106 (In Russ.)].
Zaidi KB, Rich JB, Sunderland KM, et al. Methods for improving screening for vascular cognitive impairment using the Montreal Cognitive Assessment. Can J Neurol Sci. 2020;47(6):756–63. https://doi.org/10.1017/cjn.2020.121
Wechsler D. The measurement of adult intelligence. Baltimore, MD: The Williams & Wilkins Company. 1939.
Wechsler D. Wechsler adult intelligence scale — Revised manual. New York: Psychological Corporation. 1981.
Jaeger J. Digit symbol substitution test: The case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38(5):513–19. https://doi.org/10.1097/JCP.0000000000000941
Chou MY, Nishita Y, Nakagawa T, et al. Role of gait speed and grip strength in predicting 10-year cognitive decline among community-dwelling older people. BMC Geriatr. 2019;19(1):186. https://doi.org/10.1186/s12877-019-1199-7
Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119–26. https://doi.org/10.1111/j.1532-5415.1986.tb05480.x
VanSwearingen JM, Brach JS. Making geriatric assessment work: selecting useful measures. Phys Ther. 2001;81(6):1233–52. https://doi.org/10.1093/ptj/81.6.1233
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25. https://doi.org/10.1016/0022-3999(94)00125-o
Vegetative disorders: clinic, treatment, diagnosis. Ed. by Vein A.M. Moscow: Meditsinskoye informatsionnoye agentstvo = Medical Information Agency. 2000;752 pp. (In Russ.).
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6): 473–83.
Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25(24):3130–39. https://doi.org/10.1097/00007632-200012150-00008
Shchulkin AV. Effect of Mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2): 35–39 (In Russ.)].